Sign in
4

Changes in Ownership

Axsome Therapeutics, Inc. Filed Acc 0001193125-26-340688

Chief Executive Officer sold 49,664 shares at an average $212.19 ($10,538,305)

  • Chief Executive Officer acquired 49,664 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
TABUTEAU HERRIOT Chief Executive Officer 2026-08-05 Option exercise 10b5-1 +45,004 $4.95 $222,770 52,233 D: show line 1 in the form
TABUTEAU HERRIOT Chief Executive Officer 2026-08-05 Sale 10b5-1 −45,004 $212.01 $9,541,298 7,229 D: show line 2 in the form
TABUTEAU HERRIOT Chief Executive Officer 2026-08-06 Option exercise 10b5-1 +4,660 $4.95 $23,067 11,889 D: show line 3 in the form
TABUTEAU HERRIOT Chief Executive Officer 2026-08-06 Sale 10b5-1 −4,660 $213.95 $997,007 7,229 D: show line 4 in the form
Open-market sales · 49,664 sh · avg $212.19 · $10,538,305

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
TABUTEAU HERRIOT Chief Executive Officer 2026-08-05 Option exercise · Stock Option (Right to Buy) 10b5-1 −45,004 4,660 D: show line 5 in the form
TABUTEAU HERRIOT Chief Executive Officer 2026-08-06 Option exercise · Stock Option (Right to Buy) 10b5-1 −4,660 0 D: show line 6 in the form
Loading xslF345X06/ownership.xml…